Omvoh™
Drug class
- Biologic/biosimilar
- IL-23 inhibitor
Generic name
Mirikizumab-mrkz
Safety
Efficacy
Convenience
Indications
Approved for moderate to severe ulcerative colitis in adults.
How it works
By inhibiting specific proteins that cause inflammation, biologic medications reduce disease activity and severity.
Drug interactions
Use caution with or avoid other immunosuppresive medications. Do not use live vaccines while you're using this medication.
Pre-treatment screening tests
Liver enzymes and bilirubin levels, age-appropriate vaccinations, tuberculosis.
Tests during screening
Monitor for hypersensitivity reactions especially when starting treatment. Evaluate liver transaminases; monitor for signs/symptoms of tuberculosis infection disease.
Payment options
https://omvoh.lilly.com/savings-supportRoute of administration
Frequency
Every 4 weeks, 2 injections for maintenance dose
Side effects
Upper respiratory infections (flu or colds), joint pain, injection site reaction, headache, rash, and herpes viral infections.
Contraindications
Serious hypersensitivity reaction to mirikizumab or any component of the formulation.
Safety information
Signs of infection like fever and chills, joint pain, headache, liver problems, shortness of breath, muscle aches, and signs of a allergic reaction, such as face swelling, fainting, dizziness, hives, and shortness of breath.